Septal myectomy for obstructive hypertrophic cardiomyopathy: the gold standard

Joseph A. Dearani, Hartzell V Schaff, Steve R. Ommen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Septal myectomy effectively and definitively relieves LVOT obstruction and cardiac symptoms in adults and children with obstructive hypertrophic cardiomyopathy (HCM). Abnormalities of the mitral valve can be addressed without the need for mitral valve replacement in almost all circumstances. Concomitant mitral valve repair for myxomatous disease requires minor modifications when performed in conjunction with septal myectomy; mitral valve replacement is rarely necessary. In experienced centers, early mortality for isolated septal myectomy is low (approximately 1%) and overall results are excellent and continue to improve in the current era. Symptomatic improvement with myectomy is expected for most; 90% of patients improve by at least one functional class, and most remain improved on late follow-up. Late survivorship is improved compared to nonoperated patients with obstructive HCM, and myectomy may be associated with reduced risk of sudden cardiac death. These results should serve as the gold standard and a basis for comparison with newer nonsurgical modalities, i. e., septal alcohol ablation.

Original languageEnglish (US)
Pages (from-to)307-311
Number of pages5
JournalZhonghua xin xue guan bing za zhi [Chinese journal of cardiovascular diseases]
Volume37
Issue number4
StatePublished - Apr 2009

Fingerprint

Hypertrophic Cardiomyopathy
Mitral Valve
Sudden Cardiac Death
Survival Rate
Alcohols
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Septal myectomy for obstructive hypertrophic cardiomyopathy : the gold standard. / Dearani, Joseph A.; Schaff, Hartzell V; Ommen, Steve R.

In: Zhonghua xin xue guan bing za zhi [Chinese journal of cardiovascular diseases], Vol. 37, No. 4, 04.2009, p. 307-311.

Research output: Contribution to journalArticle

@article{0011dc7ace1d4112a857d76f022d9548,
title = "Septal myectomy for obstructive hypertrophic cardiomyopathy: the gold standard",
abstract = "Septal myectomy effectively and definitively relieves LVOT obstruction and cardiac symptoms in adults and children with obstructive hypertrophic cardiomyopathy (HCM). Abnormalities of the mitral valve can be addressed without the need for mitral valve replacement in almost all circumstances. Concomitant mitral valve repair for myxomatous disease requires minor modifications when performed in conjunction with septal myectomy; mitral valve replacement is rarely necessary. In experienced centers, early mortality for isolated septal myectomy is low (approximately 1{\%}) and overall results are excellent and continue to improve in the current era. Symptomatic improvement with myectomy is expected for most; 90{\%} of patients improve by at least one functional class, and most remain improved on late follow-up. Late survivorship is improved compared to nonoperated patients with obstructive HCM, and myectomy may be associated with reduced risk of sudden cardiac death. These results should serve as the gold standard and a basis for comparison with newer nonsurgical modalities, i. e., septal alcohol ablation.",
author = "Dearani, {Joseph A.} and Schaff, {Hartzell V} and Ommen, {Steve R.}",
year = "2009",
month = "4",
language = "English (US)",
volume = "37",
pages = "307--311",
journal = "Chinese Journal of Cardiology",
issn = "0253-3758",
publisher = "Chinese Medical Association",
number = "4",

}

TY - JOUR

T1 - Septal myectomy for obstructive hypertrophic cardiomyopathy

T2 - the gold standard

AU - Dearani, Joseph A.

AU - Schaff, Hartzell V

AU - Ommen, Steve R.

PY - 2009/4

Y1 - 2009/4

N2 - Septal myectomy effectively and definitively relieves LVOT obstruction and cardiac symptoms in adults and children with obstructive hypertrophic cardiomyopathy (HCM). Abnormalities of the mitral valve can be addressed without the need for mitral valve replacement in almost all circumstances. Concomitant mitral valve repair for myxomatous disease requires minor modifications when performed in conjunction with septal myectomy; mitral valve replacement is rarely necessary. In experienced centers, early mortality for isolated septal myectomy is low (approximately 1%) and overall results are excellent and continue to improve in the current era. Symptomatic improvement with myectomy is expected for most; 90% of patients improve by at least one functional class, and most remain improved on late follow-up. Late survivorship is improved compared to nonoperated patients with obstructive HCM, and myectomy may be associated with reduced risk of sudden cardiac death. These results should serve as the gold standard and a basis for comparison with newer nonsurgical modalities, i. e., septal alcohol ablation.

AB - Septal myectomy effectively and definitively relieves LVOT obstruction and cardiac symptoms in adults and children with obstructive hypertrophic cardiomyopathy (HCM). Abnormalities of the mitral valve can be addressed without the need for mitral valve replacement in almost all circumstances. Concomitant mitral valve repair for myxomatous disease requires minor modifications when performed in conjunction with septal myectomy; mitral valve replacement is rarely necessary. In experienced centers, early mortality for isolated septal myectomy is low (approximately 1%) and overall results are excellent and continue to improve in the current era. Symptomatic improvement with myectomy is expected for most; 90% of patients improve by at least one functional class, and most remain improved on late follow-up. Late survivorship is improved compared to nonoperated patients with obstructive HCM, and myectomy may be associated with reduced risk of sudden cardiac death. These results should serve as the gold standard and a basis for comparison with newer nonsurgical modalities, i. e., septal alcohol ablation.

UR - http://www.scopus.com/inward/record.url?scp=73949127232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949127232&partnerID=8YFLogxK

M3 - Article

C2 - 19791464

AN - SCOPUS:73949127232

VL - 37

SP - 307

EP - 311

JO - Chinese Journal of Cardiology

JF - Chinese Journal of Cardiology

SN - 0253-3758

IS - 4

ER -